Loncastuximab tesirine-lpyl



Drug updated on 11/29/2023

Dosage FormInjection (intravenous; 10 mg powder for reconstitution)
Drug ClassMultiple
Ongoing and
Completed Studies


  • For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.

Product Monograph / Prescribing Information

Document TitleYearSource
Zynlonta (loncastuximab tesirine-lpyl) Prescribing Information.2022ADC Therapeutics America, Murray Hill, New Jersey

Randomized Controlled Trials